Vytrus Biotech, a company specialising in active ingredients derived from plant biotechnology for the cosmetics industry, has published its unaudited preliminary results for the first half of 2025. The company reported a global sales increase of +75% during the first six months of 2025 compared to the same period in 2024, reaching a turnover of €4.38 million. Sales in the second quarter of 2025 totalled €2.25 million, reflecting a +74% year-on-year increase.
Growth Across All Geographic Regions
Sales in the European Union, including Spain, grew by 76% in H1 2025. Meanwhile, the USA recorded a 49% increase in the first half of the year compared to 2024. The APAC region (Asia-Pacific) experienced the most significant growth, with a 154% increase in sales, driven mainly by markets such as India. In Latin America, sales grew by 48%, with Brazil, Colombia, and Mexico as the leading markets. Vytrus has now sold its products in a total of 47 countries.
The growth achieved by June 2025 has boosted Vytrus’s annualised sales (sales over the last 12 months) to €6.9 million, marking an all-time high for the company.
The start of direct commercial operations in Spain and France, as well as strong performance from Vytrus products featuring Exosomic Peptides technology, contributed significantly to H1 sales growth. Among product categories, anti-ageing, hair care, and brightening lines showed the strongest performance.
This solid sales evolution, combined with rigorous operating cost management, enabled Vytrus to increase its EBITDA by 111% compared to the same period in 2024, reaching €2.08 million.
These strong figures support the company’s strategic outlook. In early 2024, Vytrus announced its Strategic Plan, aiming to achieve €12 million in revenue and €5 million in EBITDA by 2027.
Product Innovation and a Growing Portfolio of 22 Active Ingredients
In April 2025, Vytrus launched a new proprietary ingredient, CLARIVINE™, a 100% natural biotech active based on grapevine stem cells. Leveraging advanced plant biotechnology, CLARIVINE™ introduces an innovative approach to skincare by mimicking the effects of intermittent fasting on skin cells to promote skin longevity. This mechanism activates key regenerative pathways that enhance skin texture, tone, dark spots, and pigmentation, while improving hydration and the appearance of wrinkles—with visible results in just 14 days.
The result is an immediate illuminating, rejuvenating, and smoothing effect—the coveted glass skin—combined with scientifically proven cell longevity benefits, clinically validated on both Asian and Caucasian volunteers. With this launch, Vytrus now has 22 active ingredients on the market in 2025.
CLARIVINE™ was awarded the Silver Best Ingredient Award at the in-cosmetics Global Innovation Awards 2025 (held in Amsterdam in April) and also received the ICI Indonesia Innovation Award 2025. Additionally, two other Vytrus ingredients featuring natural plant-derived exosomes—CENTELLA REVERSA™ and CAPILIA LONGA™—were honoured at the BSB Innovation Awards 2025, a benchmark in the European cosmetics industry.
Furthermore, in May 2025, the United States Patent Office granted Vytrus a patent protecting the wound-healing applications of several innovations in its portfolio. The patent, titled “CELL-FREE PLANT CELL CULTURE SUSPENSION SUPERNATANT WITH RE-YOUTH ACTIVITY AND/OR WOUND HEALING ACTIVITY OVER SKIN CELLS”, is valid until 11 March 2038.